Anavex Historical Cash Flow
| AVXL Stock | USD 9.46 0.43 4.76% |
Analysis of Anavex Life cash flow over time is an excellent tool to project Anavex Life Sciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 3 M or Capital Expenditures of 0.0 as it is a great indicator of Anavex Life ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Anavex Life Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Anavex Life Sciences is a good buy for the upcoming year.
Anavex |
About Anavex Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Anavex balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Anavex's non-liquid assets can be easily converted into cash.
Anavex Life Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Depreciation
Depreciation indicates how much of Anavex Life Sciences value has been used up. For tax purposes Anavex Life can deduct the cost of the tangible assets it purchases as business expenses. However, Anavex Life Sciences must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most accounts from Anavex Life's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Anavex Life Sciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anavex Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. At this time, Anavex Life's Cash Flows Other Operating is quite stable compared to the past year. Change To Netincome is expected to rise to about 20.8 M this year, although the value of Free Cash Flow is projected to rise to (23.8 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Begin Period Cash Flow | 152.1M | 149.2M | 171.5M | 180.1M | End Period Cash Flow | 149.2M | 151.0M | 173.7M | 182.4M |
Anavex Life cash flow statement Correlations
Click cells to compare fundamentals
Anavex Life Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Anavex Life cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 7.1M | 122.9M | (2.9M) | 1.9M | 2.1M | 2.0M | |
| Free Cash Flow | (21.3M) | (30.4M) | (24.2M) | (27.8M) | (25.0M) | (23.8M) | |
| Change In Working Capital | 116.5K | (706.4K) | 5.4M | 2.5M | 2.9M | 3.0M | |
| Total Cash From Operating Activities | (21.3M) | (30.4M) | (24.2M) | (27.8M) | (25.0M) | (23.8M) | |
| Net Income | (26.3M) | (37.9M) | (48.0M) | (47.5M) | (42.8M) | (40.6M) | |
| Total Cash From Financing Activities | 28.4M | 153.2M | 21.3M | 29.7M | 34.1M | 18.0M | |
| End Period Cash Flow | 29.2M | 152.1M | 149.2M | 151.0M | 173.7M | 182.4M | |
| Begin Period Cash Flow | 22.2M | 29.2M | 152.1M | 149.2M | 171.5M | 180.1M | |
| Other Cashflows From Financing Activities | (403.8K) | 23.4K | 303K | 1.8M | 1.6M | 827.1K | |
| Other Non Cash Items | 6.6M | 11.8M | 13.3M | 845K | 971.8K | 923.2K | |
| Stock Based Compensation | 4.9M | 8.2M | 18.4M | 16.4M | 18.8M | 19.8M | |
| Sale Purchase Of Stock | 17.8M | 28.4M | 153.2M | 21.3M | 24.5M | 27.6M | |
| Cash And Cash Equivalents Changes | (745.0K) | 7.1M | 122.9M | (2.9M) | (3.4M) | (3.2M) | |
| Cash Flows Other Operating | 954.3K | (2.1M) | (3.8M) | 5.9M | 6.8M | 7.2M | |
| Change To Netincome | 4.9M | 8.2M | 18.4M | 17.2M | 19.8M | 20.8M | |
| Change To Liabilities | 2.3M | 1.2M | (915.0K) | 970K | 1.1M | 826.8K | |
| Change To Inventory | 2.2M | 4.3M | (5.9M) | (484K) | (435.6K) | (413.8K) | |
| Change To Account Receivables | (2.2M) | (4.3M) | 5.9M | 484K | 556.6K | 584.4K | |
| Change To Operating Activities | (349.2K) | (1.9M) | 6.3M | 1.5M | 1.8M | 1.9M | |
| Issuance Of Capital Stock | 28.8M | 153.2M | 21.0M | 27.9M | 32.1M | 47.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anavex Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Return On Assets (0.20) | Return On Equity (0.30) |
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.